Cormedix Inc (CRMD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cormedix Inc   (NASDAQ: CRMD)


Cormedix Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cormedix Inc's ROI in the second quarter of 2026?
Cormedix Inc achieved a return on average invested assets (ROI) of 1.36 % in its second quarter of 2026, this is above CRMD's average return on investment of -450.14%.
Cormedix Inc invested over the 12 months ending in its second quarter of 2026 $669 million

ROI has improved compared to -6.56% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 174 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 2954, from total ROI ranking in the first quarter of 2026 at 3784.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 550.06 % 774.74 % 570.57 % 278.47 % 56.78 %
Y / Y Net Income Change TTM -44.21 % - - - -
Investment (TTM) in Millions 717 690 652 617 221
Return On Investment (TTM) 1.36 % -6.56 % -15.47 % 56.64 % 15.9 %
CRMD's Overall Ranking # 2954 # 3784 # 80 # 425 # 3644
Seq. Investment Change TTM 22.74 % 38.42 % 60.35 % 138.62 % 65.16 %
Seq. Net Income Change TTM - - - 749.9 % -
Net Income (TTM) in Millions 9 -36 -61 139 16

CRMD Company Profile >> Back to CRMD Roi Comparisons >> See Annual CRMD Return On Investment



Return On Investment CRMD's Ranking
Within: No.
Industry # 59
Sector # 175
Overall # 2954

Return On Investment Statistics
High Average Low
56.64 %
-450.14 %
-2004.93 %
(Sep 30 2025)   (Sep 30 2018)



  News about Cormedix Inc Return on Investment ROI

DefenCath: Pioneering the Fight Against Life-Threatening Infections

January 8, 2024

CorMedix Inc. Sets the Stage for Life-Saving Breakthrough with Commercial and Operational Updates
Berkeley Heights, N.J., Jan. 08, 2024 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company dedicated to developing and commercializing therapeutic products for preventing and treating life-threatening diseases and conditions, has recently divulged a series of commercial and operational updates that are poised to revolutionize the healthcare landscape. With the highly anticipated launch of their groundbreaking product, DefenCath, CorMedix Inc. is charting a new course in the fight against life-threatening infections.
DefenCath, CorMedix s flagship product, is a cutting-edge therapeutic catheter lock solution that aims to prevent catheter-related bloodstream infections (CRBSIs) in patients requiring hemodialysis. This devastating condition affects thousands of individuals worldwide, leading to severe illnesses and even death. By introducing DefenCath, CorMedix Inc. hopes to transform the way this life-threatening disease is managed, ultimately saving countless lives and decreasing healthcare costs.
The commercial and operational updates announced by CorMedix Inc. illustrate the company s commitment to not only bringing DefenCath to market but also driving its success once it becomes available. The updates include key strategic partnerships, enhanced manufacturing capabilities, and crucial regulatory approvals that will propel DefenCath into the forefront of the medical field.





Financial Statements
Cormedix Inc's II. Quarter Investments $ 717 Millions CRMD's Balance sheet
Cormedix Inc's II. Quarter Income $ 65 Millions Quarterly CRMD's Income Statement
CRMD's Income by Division See CRMD's Income by Division


CRMD Annual Return On Investment (Mar 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 115 85 71 56 64
Y / Y Investment Growth 35.51 % 20.3 % 26.79 % -12.38 % 40.88 %
Net Income in Millions 21 -18 -46 -30 -28
Y / Y Net Income Growth - - - - -
Annual Return On Investment 17.92 % -21.09 % -65.58 % -53.3 % -44.36 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 17.92 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CRMD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CRMD's Competitors
Subscribers only: Roi for Cormedix Inc's Suppliers
Subscribers only: Return On Investment for CRMD's Customers

Other Ratios
CRMD's Roa CRMD's Inventory Turnover Ratio CRMD's Growth Rates CRMD's Dividend Statistics
CRMD's Profitability Ratios CRMD's Asset Turnover Ratio CRMD's Dividend Growth
CRMD's Roe CRMD's Valuation Ratios CRMD's Financial Strength Ratios CRMD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Ardent Health Inc   3.74 %
Collegium Pharmaceutical Inc   3.72 %
Merck and Co Inc   3.24 %
Community Health Systems Inc   3.12 %
National Vision Holdings Inc   2.99 %
Teva Pharmaceutical Industries Limited  2.66 %
Lifestance Health Group Inc   2.61 %
Conmed Corporation  2.57 %
Pfizer Inc  2.53 %
Mimedx Group Inc   2.38 %
Bio rad Laboratories Inc   2.34 %
Lifemd Inc   2.32 %
Alkermes Plc   2.31 %
Becton Dickinson And Company  2.22 %
Revvity Inc  2.18 %
Envista Holdings Corporation  2.06 %
Immucell Corporation  1.95 %
Atricure Inc   1.84 %
Black Hawk Acquisition Corporation  1.79 %
Omada Health Inc   1.70 %
Arvinas Inc   1.53 %
Repligen Corp  1.41 %
Cormedix Inc   1.31 %
Pacira Biosciences inc   1.29 %
Waters Corporation  1.20 %
Surgery Partners Inc   1.02 %
Warby Parker Inc   0.98 %
Staar Surgical Co  0.98 %
Biomarin Pharmaceutical Inc  0.91 %
Icu Medical Inc  0.87 %

Date modified: 2026-09-03T11:39:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.